The ECDC updates are based on available data reported through the European Surveillance System (TESSy) by the national public health authorities of EU/EEA countries.
ECDC regularly assesses new evidence on variants detected through epidemic intelligence, rules-based genomic variant screening or other scientific sources.
ECDC is organising a physical workshop between 16 and 18 April 2024 with national experts to develop a public health guidance to support the assessment of the risk of locally-acquired Aedes-borne viral diseases in the EU/EEA.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Information on autochthonous vectorial transmission of dengue in mainland EU/EEA, including location, period, number of cases, virus serotype and mode of transmission.